The present invention relates to compounds that have zinc and/or iron ionophore activity and their use in treating diseases that are modulated by reducing zinc and/or iron. In particular embodiments, the compounds are compounds of formula (I): ##STR00001##

There is provided novel agricultural chemicals, in particular herbicides. A ketone or oxime compound or a salt thereof of Formula (1):

##STR00001##

wherein B is a ring of any one of B-1, B-2, or B-3, Q is an oxygen atom, a sulfur atom, NOR.sup.7, etc., R.sup.6 is a hydrogen atom, C.sub.1-6 alkyl, etc., R.sup.7 is a hydrogen atom, C.sub.1-6 alkyl, etc., R.sup.8a, R.sup.8b, R.sup.9a, R.sup.9b, R.sup.10, R.sup.11, R.sup.12, R.sup.13, and R.sup.14 are each independently a hydrogen atom, C.sub.1-6 alkyl, etc., m is an integer of 1 or 2, n is an integer of 0, 1 or 2; and a herbicide including the compound or salt thereof.

There is provided novel agricultural chemicals, in particular herbicides. A ketone or oxime compound or a salt thereof of Formula (1):

##STR00001##

wherein B is a ring of any one of B-1, B-2, or B-3, Q is an oxygen atom, a sulfur atom, NOR.sup.7, etc., R.sup.6 is a hydrogen atom, C.sub.1-6 alkyl, etc., R.sup.7 is a hydrogen atom, C.sub.1-6 alkyl, etc., R.sup.8a, R.sup.8b, R.sup.9a, R.sup.9b, R.sup.10, R.sup.11, R.sup.12, R.sup.13, and R.sup.14 are each independently a hydrogen atom, C.sub.1-6 alkyl, etc., m is an integer of 1 or 2, n is an integer of 0, 1 or 2; and a herbicide including the compound or salt thereof.

Comparing to conventional electrochromic material showing a primary drawback of high manufacturing cost due to low synthetic yield, the inventors of the present invention modulate the chemical structure of a traditional viologen compounds so as to develop a novel electrochromic material performing an excellent advantage of low manufacturing cost resulted from high recovery rate. Moreover, differing from conventional electrochromic devices (ECD) installed with the conventional electrochromic material, the inventors of the present invention also propose an anti-dazzle mirror having the novel electrochromic material, wherein the proposed anti-dazzle mirror shows an outstanding reflectivity performance.

Comparing to conventional electrochromic material showing a primary drawback of high manufacturing cost due to low synthetic yield, the inventors of the present invention modulate the chemical structure of a traditional viologen compounds so as to develop a novel electrochromic material performing an excellent advantage of low manufacturing cost resulted from high recovery rate. Moreover, differing from conventional electrochromic devices (ECD) installed with the conventional electrochromic material, the inventors of the present invention also propose an anti-dazzle mirror having the novel electrochromic material, wherein the proposed anti-dazzle mirror shows an outstanding reflectivity performance.

The present invention relates to a medicament design pocket of ODC. Based on the crystal structure of human ODC, the binding site area of putrescine and PLP ligand on the ODC homodimer interface is the medicament pocket, which is used for screening or designing or modifying inhibitors of human ODC, or screening or designing or modifying inhibitors of non-human ODC, or screening or designing or modifying protein inhibitor highly homologous to the binding site of putrescine and pyridoxal phosphate on the interface of ODC homodimer. The invention also provides the structure of the inhibitor and its application thereof. The technical solutions in the invention provide reliable theoretical basis for the research and development of human ODC, the prevention, treatment and diagnosis of tumors and pathogenic microbial infections, and the research and development and preparation of medicaments for the treatment of tumors or pathogenic microbial infections.

The present invention relates to a medicament design pocket of ODC. Based on the crystal structure of human ODC, the binding site area of putrescine and PLP ligand on the ODC homodimer interface is the medicament pocket, which is used for screening or designing or modifying inhibitors of human ODC, or screening or designing or modifying inhibitors of non-human ODC, or screening or designing or modifying protein inhibitor highly homologous to the binding site of putrescine and pyridoxal phosphate on the interface of ODC homodimer. The invention also provides the structure of the inhibitor and its application thereof. The technical solutions in the invention provide reliable theoretical basis for the research and development of human ODC, the prevention, treatment and diagnosis of tumors and pathogenic microbial infections, and the research and development and preparation of medicaments for the treatment of tumors or pathogenic microbial infections.

The purpose of the present invention is to provide a modified polymer that significantly reduces heat build-up due to the modification when the modified polymer is formed into a rubber composition, a rubber composition containing the modified polymer, and a pneumatic tire in which the rubber composition is used. The modified polymer of the present invention is a modified polymer obtained by modifying a styrene-conjugated diene copolymer (A) with a nitrone compound (B). In the modified polymer, the content of styrene units in the styrene-conjugated diene copolymer (A) is 10% by mass or greater, and the proportion of vinyl bonds among all the double bonds contained in the styrene-conjugated diene copolymer (A) is 5 mol % or greater.

The purpose of the present invention is to provide a modified polymer that significantly reduces heat build-up due to the modification when the modified polymer is formed into a rubber composition, a rubber composition containing the modified polymer, and a pneumatic tire in which the rubber composition is used. The modified polymer of the present invention is a modified polymer obtained by modifying a styrene-conjugated diene copolymer (A) with a nitrone compound (B). In the modified polymer, the content of styrene units in the styrene-conjugated diene copolymer (A) is 10% by mass or greater, and the proportion of vinyl bonds among all the double bonds contained in the styrene-conjugated diene copolymer (A) is 5 mol % or greater.

This invention relates to antagonists of G3BP2, G3BP1, and ZEB1. Pharmaceutical compositions comprising G3BP2 inhibitors, methods of inhibiting G3BP2, G3BP1, and ZEB1, methods of treating cancer and inflammation, and methods of identifying an inhibitor of cancer stems cells are also provided.